|
BR122016004546B8
(pt)
|
2001-11-13 |
2021-07-27 |
Univ Pennsylvania |
vírus adenoassociado recombinante, método de geração do referido vírus e composição compreendendo o referido vírus
|
|
DK1453547T3
(en)
|
2001-12-17 |
2016-12-05 |
Univ Pennsylvania |
ADENOASSOCATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING THESE AND APPLICATIONS THEREOF
|
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
CA3072423A1
(en)
*
|
2003-09-30 |
2005-04-14 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
|
|
JP2007535541A
(ja)
|
2004-04-28 |
2007-12-06 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｅ４欠失アデノウイルス初回免疫およびｅ１欠失アデノウイルス追加免疫を用いる免疫化方式
|
|
ES2361000T3
(es)
|
2004-04-28 |
2011-06-13 |
The Trustees Of The University Of Pennsylvania |
Suministro secuencial de moléculas inmunogénicas mediante administraciones de un adenovirus y de un virus adeno-asociado.
|
|
EP3409296A1
(en)
|
2005-04-07 |
2018-12-05 |
The Trustees of the University of Pennsylvania |
Method of increasing the function of an aav vector
|
|
EP2007795B1
(en)
|
2006-03-30 |
2016-11-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid proteins
|
|
JP5479087B2
(ja)
*
|
2006-04-07 |
2014-04-23 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
アデノ随伴ウイルスファージ粒子に関する方法および組成物
|
|
CN101528916B
(zh)
|
2006-04-28 |
2013-09-04 |
宾夕法尼亚大学托管会 |
规模可调的aav生产方法
|
|
EP2016174A2
(en)
*
|
2006-04-28 |
2009-01-21 |
The Trustees of the University of Pennsylvania |
Modified aav vectors having reduced capsid immunogenicity and use thereof
|
|
HRP20161150T1
(hr)
|
2007-04-09 |
2016-11-18 |
University Of Florida Research Foundation, Inc. |
PRIPRAVCI rAAV VEKTORA KOJI IMAJU TIROZIN-MODIFICIRANE CAPSID PROTEINE I POSTUPCI ZA UPORABU
|
|
US9725485B2
(en)
*
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
EP2019143A1
(en)
*
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
|
EP2058401A1
(en)
*
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
|
US20090215879A1
(en)
*
|
2008-02-26 |
2009-08-27 |
University Of North Carolina At Chapel Hill |
Methods and compositions for adeno-associated virus (aav) with hi loop mutations
|
|
US8632764B2
(en)
|
2008-04-30 |
2014-01-21 |
University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
US8889641B2
(en)
|
2009-02-11 |
2014-11-18 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
JP6174318B2
(ja)
*
|
2009-04-30 |
2017-08-02 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
アデノ随伴ウイルス構築物を含んでなるコンダクティング気道細胞を標的とするための組成物
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
US9133479B2
(en)
*
|
2009-06-03 |
2015-09-15 |
Cedars-Sinai Medical Center |
Effective vector platform for gene transfer and gene therapy
|
|
US20120244127A1
(en)
|
2009-10-01 |
2012-09-27 |
The Trustees Of The University Of Pennsylvania |
AAV Vectors Expressing SEC10 for Treating Kidney Damage
|
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
CN102869779A
(zh)
|
2010-03-29 |
2013-01-09 |
宾夕法尼亚大学托管会 |
药理学诱导的转基因消融系统
|
|
US9546369B2
(en)
|
2010-04-23 |
2017-01-17 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
DK2561073T3
(en)
|
2010-04-23 |
2016-12-12 |
Univ Massachusetts |
Aav vectors targeted to central nervous system and methods of use thereof
|
|
WO2011133901A2
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
US10738326B2
(en)
|
2010-10-27 |
2020-08-11 |
Jichi Medical University |
Adeno-associated virus vector for gene transfer to nervous system cells
|
|
JP6042825B2
(ja)
*
|
2011-02-10 |
2016-12-14 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
|
|
BR112013020734A2
(pt)
|
2011-02-17 |
2017-06-13 |
Univ Pennsylvania |
composições e métodos para alterar a especificidade do tecido e aprimorar a transferência gênica mediada por aav9
|
|
US20140031418A1
(en)
|
2011-04-20 |
2014-01-30 |
The Trustees Of The University Of Pennsylvania |
Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
|
|
ES2661680T3
(es)
|
2011-04-21 |
2018-04-03 |
University Of Massachusetts |
Composiciones basadas en VAAr y métodos para tratar deficiencias de alfa-1 anti-tripsina
|
|
KR20220056884A
(ko)
|
2011-04-22 |
2022-05-06 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 지니는 아데노-관련 바이러스 및 이의 사용 방법
|
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
ES2857773T5
(es)
*
|
2011-08-24 |
2024-06-04 |
Univ Leland Stanford Junior |
Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
|
|
EP2764119A2
(en)
|
2011-10-05 |
2014-08-13 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
US9226936B2
(en)
|
2011-10-28 |
2016-01-05 |
The Wistar of Anatomy and Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
|
|
US10238755B2
(en)
|
2011-11-30 |
2019-03-26 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming
|
|
EP2601968A1
(en)
*
|
2011-12-06 |
2013-06-12 |
Deutsches Krebsforschungszentrum |
HPV derived polynucleic acids for therapy
|
|
WO2013103896A1
(en)
|
2012-01-06 |
2013-07-11 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
|
WO2013138522A2
(en)
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
WO2013158265A1
(en)
|
2012-04-20 |
2013-10-24 |
Genelux Corporation |
Imaging methods for oncolytic virus therapy
|
|
JP6385920B2
(ja)
*
|
2012-05-09 |
2018-09-05 |
オレゴン ヘルス アンド サイエンス ユニバーシティー |
アデノ随伴ウイルスプラスミド及びベクター
|
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
|
US12358954B2
(en)
|
2012-05-15 |
2025-07-15 |
University Of Florida Research Foundation, Incorporated |
Capsid-modified rAAV vector compositions and methods therefor
|
|
JP6199965B2
(ja)
|
2012-07-11 |
2017-09-20 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｒｐｇｒｘ連鎖性網膜変性のａａｖ媒介型遺伝子治療
|
|
FI3415167T3
(fi)
|
2012-08-01 |
2024-08-29 |
Nationwide Childrens Hospital |
Rekombinantti adeno-assosioituneen viruksen 9 intratekaalinen annostelu
|
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
|
ES2814901T3
(es)
*
|
2012-09-28 |
2021-03-29 |
Univ North Carolina Chapel Hill |
Vectores de AAV dirigidos a oligodendrocitos
|
|
WO2014055960A1
(en)
|
2012-10-05 |
2014-04-10 |
Genelux Corporation |
Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
|
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
|
EP2970946A4
(en)
*
|
2013-03-13 |
2016-09-07 |
Philadelphia Children Hospital |
ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
|
|
US10295547B2
(en)
|
2013-03-14 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
Use and treatment of di-amino acid repeat-containing proteins associated with ALS
|
|
IL298049B2
(en)
*
|
2013-03-15 |
2023-10-01 |
Univ North Carolina Chapel Hill |
Methods and compounds for ligation of paired AAV glycan vectors
|
|
SG11201507507PA
(en)
|
2013-03-15 |
2015-10-29 |
Univ Pennsylvania |
Compositions and methods for treating mpsi
|
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
|
ES2897508T3
(es)
|
2013-05-31 |
2022-03-01 |
Univ California |
Variantes de virus adenoasociados y métodos de uso de las mismas
|
|
US9585971B2
(en)
|
2013-09-13 |
2017-03-07 |
California Institute Of Technology |
Recombinant AAV capsid protein
|
|
AU2014324717B2
(en)
|
2013-09-26 |
2020-10-08 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial AAV capsid library for targeted gene therapy
|
|
WO2015054258A1
(en)
*
|
2013-10-07 |
2015-04-16 |
Kiromic, Llc |
Compositions and methods for treating cardiovascular diseases using disease-specific promoter
|
|
PL3459965T3
(pl)
*
|
2013-10-11 |
2021-07-26 |
Massachusetts Eye & Ear Infirmary |
Sposoby przewidywania sekwencji wirusa-przodka i ich zastosowania
|
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
LT3116900T
(lt)
|
2014-03-09 |
2020-12-10 |
The Trustees Of The University Of Pennsylvania |
Kompozicijos, naudotinos ornitino transkarbamilazės (otc) nepakankamumo gydymui
|
|
FI3117005T3
(fi)
|
2014-03-10 |
2024-08-29 |
Uniqure Ip Bv |
Hyönteissoluissa tuotettuja lisää parannettuja aav-vektoreita
|
|
KR102288849B1
(ko)
|
2014-03-17 |
2021-08-12 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
|
|
EP3750907A3
(en)
|
2014-03-18 |
2021-04-28 |
University of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
EP2933335A1
(en)
|
2014-04-18 |
2015-10-21 |
Genethon |
A method of treating peripheral neuropathies and motor neuron diseases
|
|
JP6983511B2
(ja)
|
2014-04-25 |
2021-12-17 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
脳中の転移乳癌および他の癌を処置するための方法および組成物
|
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
|
ES2876409T3
(es)
|
2014-04-25 |
2021-11-12 |
Univ Pennsylvania |
Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol
|
|
UA123986C2
(uk)
|
2014-05-13 |
2021-07-07 |
Дзе Трастіз Оф Дзе Юніверсіті Оф Пенсильванія |
Композиція, яка містить aav, який експресує конструкцію антитіл з подвійною специфічністю, і її застосування
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
EP2960336A1
(en)
|
2014-06-27 |
2015-12-30 |
Genethon |
Efficient systemic treatment of dystrophic muscle pathologies
|
|
WO2016049230A1
(en)
|
2014-09-24 |
2016-03-31 |
City Of Hope |
Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
JP6842410B2
(ja)
|
2014-10-03 |
2021-03-17 |
ユニバーシティ オブ マサチューセッツ |
新規の高効率ライブラリーにより同定されるａａｖベクター
|
|
CA3126536C
(en)
|
2014-10-14 |
2023-07-25 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
JP7023108B2
(ja)
|
2014-10-21 |
2022-02-21 |
ユニバーシティ オブ マサチューセッツ |
組み換えａａｖバリアントおよびその使用
|
|
BR112017009497A2
(pt)
|
2014-11-05 |
2018-02-06 |
Voyager Therapeutics, Inc. |
polinucleotídeos de aadc para o tratamento da doença de parkinson
|
|
EP3215602B1
(en)
|
2014-11-05 |
2019-12-25 |
The Research Institute at Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
|
US10570395B2
(en)
|
2014-11-14 |
2020-02-25 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
CA2967367C
(en)
|
2014-11-14 |
2023-05-16 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
KR20240063169A
(ko)
*
|
2014-11-21 |
2024-05-10 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
중추 신경계에 표적화된 aav 벡터
|
|
HK1245326A1
(zh)
|
2014-12-12 |
2018-08-24 |
Voyager Therapeutics, Inc. |
用於生产scaav的组合物和方法
|
|
JP6754361B2
(ja)
|
2014-12-16 |
2020-09-09 |
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ |
若年型バッテン病のための遺伝子療法
|
|
WO2016110518A1
(en)
|
2015-01-07 |
2016-07-14 |
Universitat Autònoma De Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
|
KR102684387B1
(ko)
|
2015-01-16 |
2024-07-11 |
유니버시티 오브 워싱톤 |
신규한 마이크로-디스트로핀 및 관련된 사용 방법
|
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
BR112017018846A2
(pt)
|
2015-03-02 |
2018-07-31 |
Adverum Biotechnologies, Inc. |
composições e métodos para entrega intravítrea de polinucleotídeos a cones retinianos.
|
|
PT3268024T
(pt)
|
2015-03-10 |
2020-12-09 |
Univ Columbia |
Construtos de vetor viral recombinante glut1 adeno associado e métodos relacionados para restaurar a expressão de glut1
|
|
ES2860712T3
(es)
*
|
2015-03-24 |
2021-10-05 |
Univ California |
Variantes de virus adenoasociados y métodos de uso de las mismas
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
US20180110877A1
(en)
|
2015-04-27 |
2018-04-26 |
The Trustees Of The University Of Pennsylvania |
DUAL AAV VECTOR SYSTEM FOR CRISPR/Cas9 MEDIATED CORRECTION OF HUMAN DISEASE
|
|
AU2016256894B2
(en)
|
2015-05-07 |
2020-11-26 |
Massachusetts Eye And Ear Infirmary |
Methods of delivering an agent to the eye
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
EP3294894B8
(en)
|
2015-05-12 |
2019-09-25 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone
|
|
US11535665B2
(en)
|
2015-05-13 |
2022-12-27 |
The Trustees Of The University Of Pennsylvania |
AAV-mediated expression of anti-influenza antibodies and methods of use thereof
|
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
|
WO2016196324A1
(en)
|
2015-05-29 |
2016-12-08 |
University Of Floridia Research Foundation, Inc. |
Methods for diagnosing huntington's disease
|
|
WO2017015637A1
(en)
|
2015-07-22 |
2017-01-26 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
JP7166168B2
(ja)
|
2015-07-30 |
2022-11-07 |
マサチューセッツ アイ アンド イヤー インファーマリー |
祖先ウイルス配列およびその使用
|
|
GB2595063B
(en)
|
2015-07-31 |
2022-03-09 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
WO2017024198A1
(en)
|
2015-08-06 |
2017-02-09 |
The Trustees Of The University Of Pennsylvania |
Glp-1 and use thereof in compositions for treating metabolic diseases
|
|
CN108351350B
(zh)
|
2015-08-25 |
2022-02-18 |
杜克大学 |
使用rna指导型内切核酸酶改善基因组工程特异性的组合物和方法
|
|
HK1257024A1
(zh)
|
2015-08-31 |
2019-10-11 |
宾夕法尼亚大学 |
用於治疗伴侣动物的aav-epo
|
|
CN108291216B
(zh)
|
2015-09-24 |
2022-09-16 |
宾夕法尼亚州大学信托人 |
用于治疗补体介导的疾病的组合物和方法
|
|
EP3831842A1
(en)
|
2015-09-28 |
2021-06-09 |
The University of North Carolina at Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
|
WO2017062750A1
(en)
|
2015-10-09 |
2017-04-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating stargardt's disease and other ocular disorders
|
|
EP3362571A4
(en)
|
2015-10-13 |
2019-07-10 |
Duke University |
GENOM ENGINEERING WITH TYPE I CRISPR SYSTEMS IN EUKARYOTIC CELLS
|
|
WO2017066764A2
(en)
|
2015-10-16 |
2017-04-20 |
William Marsh Rice University |
Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
|
|
EP3364996B1
(en)
*
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
|
WO2017070476A2
(en)
*
|
2015-10-22 |
2017-04-27 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav3 capsid library
|
|
WO2017070491A1
(en)
*
|
2015-10-23 |
2017-04-27 |
Applied Genetic Technologies Corporation |
Ophthalmic formulations
|
|
MX2018005353A
(es)
|
2015-10-28 |
2018-08-14 |
Univ Pennsylvania |
Administracion intratecal de vectores virales adenop-asociados para terapia genica.
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
KR102200642B1
(ko)
|
2015-11-05 |
2021-01-12 |
뱀부 테라퓨틱스 인코포레이티드 |
유전자 치료를 위한 변형된 프리드라이히 운동실조증 유전자 및 벡터
|
|
AU2016362477A1
(en)
|
2015-12-02 |
2018-06-14 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
WO2017160360A2
(en)
|
2015-12-11 |
2017-09-21 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
|
BR112018011711A2
(pt)
*
|
2015-12-11 |
2018-12-04 |
California Inst Of Techn |
peptídeos de direcionamento para direcionar virus adeno-associados (aav)
|
|
EP3992283A1
(en)
|
2015-12-11 |
2022-05-04 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
|
JP6990182B2
(ja)
|
2015-12-11 |
2022-02-15 |
マサチューセッツ アイ アンド イヤー インファーマリー |
蝸牛および前庭細胞に核酸を送達するための材料および方法
|
|
MX2018007080A
(es)
|
2015-12-11 |
2018-11-12 |
Univ Pennsylvania |
Terapia genica para tratar hipercolesterolemia familiar.
|
|
EP4215605A1
(en)
|
2015-12-11 |
2023-07-26 |
The Trustees of The University of Pennsylvania |
Scalable purification method for aav8
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
JP7057281B2
(ja)
|
2015-12-14 |
2022-04-19 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
眼疾患のための遺伝子療法
|
|
JP7061067B2
(ja)
|
2015-12-14 |
2022-04-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
クリグラー・ナジャー症候群の処置のための組成物
|
|
US20180353624A1
(en)
*
|
2015-12-14 |
2018-12-13 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated viral vectors useful in treatment of spinal muscular atropy
|
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
|
SG11201806270XA
(en)
|
2016-02-03 |
2018-08-30 |
Univ Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
JP2019504888A
(ja)
|
2016-02-05 |
2019-02-21 |
エモリー ユニバーシティ |
一本鎖アデノ随伴ウイルス９または自己相補型アデノ随伴ウイルス９の脳脊髄液への注射
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
US10940161B2
(en)
|
2016-04-04 |
2021-03-09 |
University Of Florida Research Foundation, Incorporated |
Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
|
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
IL262207B1
(en)
|
2016-04-15 |
2025-09-01 |
Univ Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
KR102450833B1
(ko)
|
2016-04-15 |
2022-10-05 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
혈우병 a 치료용 유전자 요법
|
|
AU2017250298B2
(en)
|
2016-04-15 |
2024-10-03 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type II
|
|
US10882914B2
(en)
|
2016-04-15 |
2021-01-05 |
Alpine Immune Sciences, Inc. |
ICOS ligand variant immunomodulatory proteins and uses thereof
|
|
IL298604A
(en)
*
|
2016-04-15 |
2023-01-01 |
Univ Pennsylvania |
Novel aav8 mutant capsids and compositions containing same
|
|
KR102764225B1
(ko)
|
2016-04-15 |
2025-02-07 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd80 변이체 면역조절 단백질 및 그의 용도
|
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
US11401527B2
(en)
|
2016-04-17 |
2022-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017192699A1
(en)
*
|
2016-05-03 |
2017-11-09 |
Children's Medical Research Institute |
Adeno-associated virus polynucleotides, polypeptides and virions
|
|
EP3445773B1
(en)
|
2016-05-13 |
2022-12-28 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
|
RU2764587C2
(ru)
|
2016-05-18 |
2022-01-18 |
Вояджер Терапьютикс, Инк. |
Способы и композиции для лечения хореи гентингтона
|
|
JP7066635B2
(ja)
|
2016-05-18 |
2022-05-13 |
ボイジャー セラピューティクス インコーポレイテッド |
調節性ポリヌクレオチド
|
|
EP3469080A4
(en)
|
2016-06-13 |
2020-01-22 |
The University of North Carolina at Chapel Hill |
OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES AND THEIR USE
|
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
AU2017292010B2
(en)
|
2016-07-08 |
2023-07-27 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving RDH12
|
|
US12214056B2
(en)
|
2016-07-19 |
2025-02-04 |
Duke University |
Therapeutic applications of CPF1-based genome editing
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
SG11201811603WA
(en)
*
|
2016-07-26 |
2019-02-27 |
Biomarin Pharm Inc |
Novel adeno-associated virus capsid proteins
|
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
KR102511979B1
(ko)
|
2016-07-29 |
2023-03-20 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법
|
|
CA3034089A1
(en)
|
2016-08-18 |
2018-02-22 |
The Regents Of The University Of California |
Crispr-cas genome engineering via a modular aav delivery system
|
|
US11298041B2
(en)
|
2016-08-30 |
2022-04-12 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
JP7577291B6
(ja)
*
|
2016-10-13 |
2024-11-26 |
ユニバーシティ オブ マサチューセッツ |
Ａａｖカプシド設計
|
|
GB2604416B
(en)
|
2016-10-18 |
2023-03-15 |
Univ Minnesota |
Tumor infiltating lymphocytes and methods of therapy
|
|
EP3528785A4
(en)
|
2016-10-19 |
2020-12-02 |
Adverum Biotechnologies, Inc. |
MODIFIED AAV CASPIDS AND USES THEREOF
|
|
EP3529361B1
(en)
|
2016-10-20 |
2021-03-24 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
JP7065852B2
(ja)
|
2016-12-01 |
2022-05-12 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
網膜変性疾患の処置のための医薬組成物
|
|
BR112019013576A2
(pt)
|
2016-12-30 |
2020-02-04 |
Univ Pennsylvania |
terapia genica para o tratamento da fenilcetonuria
|
|
KR102604096B1
(ko)
|
2016-12-30 |
2023-11-23 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
윌슨병을 치료하기 위한 유전자 치료
|
|
EP3570895A1
(en)
|
2017-01-17 |
2019-11-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors
|
|
US11535866B2
(en)
|
2017-02-01 |
2022-12-27 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating citrullenemia
|
|
US11920156B2
(en)
|
2017-02-09 |
2024-03-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (NK) cells and compositions and methods thereof
|
|
AU2018220212A1
(en)
|
2017-02-20 |
2019-08-08 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
EP3585883A4
(en)
|
2017-02-21 |
2021-04-14 |
University of Florida Research Foundation, Incorporated |
MODIFIED AAV CAPSID PROTEINS AND USES THEREOF
|
|
WO2018154096A1
(en)
|
2017-02-24 |
2018-08-30 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
LT3589730T
(lt)
|
2017-02-28 |
2024-03-12 |
The Trustees Of The University Of Pennsylvania |
Adenoasocijuoto viruso (aav) monofiletinės grupės f vektorius, ir jo panaudojimo būdai
|
|
SG10201913833PA
(en)
*
|
2017-02-28 |
2020-03-30 |
Univ Pennsylvania |
Influenza vaccines based on aav vectors
|
|
RU2019130004A
(ru)
|
2017-03-01 |
2021-04-01 |
Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания |
Генная терапия при глазных заболеваниях
|
|
US11376321B2
(en)
|
2017-03-02 |
2022-07-05 |
Genethon |
Method for removing anti-AAV antibodies from a blood-derived composition
|
|
KR20190141146A
(ko)
|
2017-03-16 |
2019-12-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l2 변이체 면역조절 단백질 및 그의 용도
|
|
KR102692556B1
(ko)
|
2017-03-16 |
2024-08-09 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l1 변이체 면역조절 단백질 및 그의 용도
|
|
MX2019010887A
(es)
|
2017-03-16 |
2019-10-15 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras de cb80 variante y usos de estas.
|
|
EP3601558A4
(en)
|
2017-03-24 |
2021-01-06 |
Lankenau Institute for Medical Research |
Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
|
|
SG11201909136PA
(en)
|
2017-03-31 |
2019-10-30 |
Staidson Beijing Biopharmaceuticals Co Ltd |
Shrna expression cassette, polynucleotide sequence carrying the same, and use thereof
|
|
EP3610016A1
(en)
|
2017-04-10 |
2020-02-19 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
|
IL269892B2
(en)
|
2017-04-14 |
2024-04-01 |
Regenxbio Inc |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells
|
|
CA3060250A1
(en)
|
2017-04-17 |
2018-10-25 |
University Of Florida Research Foundation, Incorporated |
Regulation of ran protein translation by pkr and eif2a-p pathways
|
|
EP3634986A4
(en)
|
2017-04-24 |
2021-09-08 |
The Trustees of The University of Pennsylvania |
GENE THERAPY FOR EYE DISORDERS
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
SG11201909868YA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
US11859179B2
(en)
|
2017-05-09 |
2024-01-02 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (ALS)
|
|
CA3061968A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
|
|
CA3061655A1
(en)
|
2017-05-11 |
2018-11-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
EP3630986A4
(en)
|
2017-05-31 |
2021-08-11 |
The Trustees of The University of Pennsylvania |
GENE THERAPY FOR TREATMENT OF PEROXISOMAL DISEASES
|
|
WO2018232149A1
(en)
|
2017-06-14 |
2018-12-20 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
JP2020530307A
(ja)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス，インコーポレーテッド |
遺伝子治療のためのアデノ随伴ウイルスベクター
|
|
KR20250023600A
(ko)
|
2017-06-30 |
2025-02-18 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법
|
|
JP2020526514A
(ja)
|
2017-07-06 |
2020-08-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ｉ型を治療するための遺伝子治療
|
|
PL3648783T3
(pl)
|
2017-07-07 |
2024-11-18 |
Genethon |
Nowe polinukleotydy kodujące ludzkie białko fkrp
|
|
JP7229989B2
(ja)
|
2017-07-17 |
2023-02-28 |
ボイジャー セラピューティクス インコーポレイテッド |
軌道アレイガイドシステム
|
|
BR112020001060A2
(pt)
|
2017-07-27 |
2020-07-14 |
Novartis Ag |
variantes de trem2 resistentes a shedase
|
|
AU2018311069A1
(en)
|
2017-08-03 |
2020-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
CA3059995A1
(en)
|
2017-08-28 |
2019-03-07 |
The Regents Of The University Of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
KR102743219B1
(ko)
|
2017-09-20 |
2024-12-17 |
4디 몰레큘러 테라퓨틱스 아이엔씨. |
아데노-관련 바이러스 변이체 캡시드 및 그 용도
|
|
US11739330B2
(en)
|
2017-09-22 |
2023-08-29 |
University Of Massachusetts |
SOD1 dual expression vectors and uses thereof
|
|
TWI835747B
(zh)
|
2017-09-22 |
2024-03-21 |
賓州大學委員會 |
用於治療黏多醣病 ii 型之基因治療
|
|
JP2020535448A
(ja)
|
2017-09-25 |
2020-12-03 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． |
Ｒａｎタンパク質の検出のための免役アッセイ
|
|
WO2019067587A1
(en)
|
2017-09-26 |
2019-04-04 |
University Of Florida Research Foundation, Incorporated |
USE OF METFORMIN AND ANALOGUES THEREOF TO REDUCE RAN PROTEIN RATES DURING TREATMENT OF NEUROLOGICAL DISORDERS
|
|
EP3687582A4
(en)
|
2017-09-29 |
2021-07-14 |
Voyager Therapeutics, Inc. |
RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
CA3079565A1
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
|
|
KR20200067195A
(ko)
|
2017-10-18 |
2020-06-11 |
리젠엑스바이오 인크. |
완전-인간 번역후 변형된 항체 치료제
|
|
WO2019079520A2
(en)
|
2017-10-18 |
2019-04-25 |
Alpine Immune Sciences, Inc. |
ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF
|
|
KR102763312B1
(ko)
|
2017-10-20 |
2025-02-07 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법
|
|
UA127831C2
(uk)
|
2017-11-27 |
2024-01-17 |
4Д Молекьюлар Терапьютикс Інк. |
Капсид аденоасоційованого вірусу та його застосування для інгібування ангіогенезу
|
|
BR112020010735A2
(pt)
|
2017-11-30 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
terapia genética para mucopolissacaridose iii a
|
|
KR20200104864A
(ko)
|
2017-11-30 |
2020-09-04 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
뮤코다당류증 iiib형에 대한 유전자 요법
|
|
CA3086045A1
(en)
|
2017-12-19 |
2019-06-27 |
Akouos, Inc. |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
|
WO2019136179A1
(en)
|
2018-01-03 |
2019-07-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
CA3088323A1
(en)
|
2018-01-17 |
2019-07-25 |
Adrenas Therapeutics, Inc. |
Adeno-associated virus gene therapy for 21-hydroxylase deficiency
|
|
US20190256867A1
(en)
|
2018-02-01 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
EP3755795A4
(en)
|
2018-02-19 |
2022-07-20 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
|
|
WO2019168961A1
(en)
*
|
2018-02-27 |
2019-09-06 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
|
KR102848518B1
(ko)
|
2018-02-27 |
2025-08-22 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
캡시드 탈아미드화가 감소된 신규 아데노-연관 바이러스(aav) 벡터 및 이의 용도
|
|
IL317905A
(en)
*
|
2018-03-16 |
2025-02-01 |
Res Inst Nationwide Childrens Hospital |
Increasing tissue-specific gene delivery through capsid modification
|
|
JP2021519581A
(ja)
|
2018-04-03 |
2021-08-12 |
ストライドバイオ，インコーポレイテッド |
抗体を回避するウイルスベクター
|
|
KR20210006358A
(ko)
|
2018-04-03 |
2021-01-18 |
스트라이드바이오 인코포레이티드 |
안 조직을 표적으로 하기 위한 바이러스 벡터
|
|
CN112272672A
(zh)
|
2018-04-03 |
2021-01-26 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
KR20210015770A
(ko)
|
2018-04-05 |
2021-02-10 |
제네똥 |
감소된 간 향성을 갖는 AAV9과 AAVrh74의 하이브리드 재조합 아데노-관련 바이러스 세로타입
|
|
EP3775266A4
(en)
|
2018-04-05 |
2021-06-30 |
Massachusetts Eye and Ear Infirmary |
METHOD OF MANUFACTURING AND USING COMBINATIONAL BAR-CODED NUCLEIC ACID LIBRARIES WITH DEFINED VARIATION
|
|
JP7575273B2
(ja)
|
2018-04-16 |
2024-10-29 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
デュシェンヌ型筋ジストロフィーを治療するための組成物及び方法
|
|
MX2020010994A
(es)
|
2018-04-18 |
2021-01-08 |
Univ Columbia |
Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial.
|
|
MX2020011386A
(es)
|
2018-04-27 |
2021-01-29 |
Spacecraft Seven Llc |
Terapia genica para la degeneracion del snc.
|
|
EP3788165A1
(en)
|
2018-04-29 |
2021-03-10 |
REGENXBIO Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
CA3098565A1
(en)
|
2018-04-29 |
2019-11-07 |
Claire G. ZHANG |
Scalable clarification process for recombinant aav production
|
|
AU2019265663B2
(en)
|
2018-05-08 |
2024-06-13 |
Rutgers, The State University Of New Jersey |
AAV-compatible laminin-linker polymerization proteins
|
|
SG11202010830WA
(en)
|
2018-05-09 |
2020-11-27 |
Biomarin Pharm Inc |
Methods of treating phenylketonuria
|
|
ES3050313T3
(en)
|
2018-05-11 |
2025-12-19 |
Massachusetts Eye & Ear Infirmary |
Liver-specific tropism of adeno-associated viruses
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
US12338267B2
(en)
|
2018-05-15 |
2025-06-24 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
EP3793616A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
JP2021523914A
(ja)
|
2018-05-15 |
2021-09-09 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
パーキンソン病を治療するための組成物および方法
|
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
AU2019282239B2
(en)
|
2018-06-04 |
2024-06-06 |
Calidi Biotherapeutics (Nevada), Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
EP3807404A1
(en)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
IL279193B2
(en)
|
2018-06-14 |
2025-07-01 |
Regenxbio Inc |
Anion exchange chromatography for recombinant AAV production
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
SG11202100022SA
(en)
|
2018-07-12 |
2021-01-28 |
Rocket Pharmaceuticals Ltd |
Gene therapy vectors for treatment of danon disease
|
|
WO2020016655A2
(en)
|
2018-07-17 |
2020-01-23 |
Helixmith Co., Ltd. |
Treatment of neuropathy with dna constructs expressing igf-1 isoforms
|
|
US20210322473A1
(en)
*
|
2018-07-18 |
2021-10-21 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
|
US20210355454A1
(en)
|
2018-07-24 |
2021-11-18 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
EP3830107A2
(en)
*
|
2018-08-03 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
AU2019319976B2
(en)
|
2018-08-10 |
2025-08-14 |
Regenxbio Inc. |
Scalable method for recombinant AAV production
|
|
EP3837349A4
(en)
|
2018-08-16 |
2022-06-08 |
The Regents of the University of California |
CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLISTER FOR INDUCING CELL VESICLES PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF
|
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
WO2020047467A2
(en)
|
2018-08-30 |
2020-03-05 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with myocardin and ascl1
|
|
JP7624724B2
(ja)
|
2018-09-26 |
2025-01-31 |
カリフォルニア インスティテュート オブ テクノロジー |
標的遺伝子療法のためのアデノ随伴ウイルス組成物
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
US20230040603A1
(en)
|
2018-10-01 |
2023-02-09 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating gm1 gangliosidosis
|
|
JP2022513318A
(ja)
|
2018-10-01 |
2022-02-07 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
プロピオン酸血症を処置するための遺伝子治療
|
|
SG11202103250UA
(en)
|
2018-10-01 |
2021-04-29 |
Toru Miyazaki |
Therapeutic agent for neurodegenerative disease
|
|
CA3115217A1
(en)
|
2018-10-02 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
|
AU2019354793A1
(en)
*
|
2018-10-05 |
2021-05-13 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding AAV production proteins
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CN112912518A
(zh)
|
2018-10-15 |
2021-06-04 |
再生生物股份有限公司 |
用于测量复制缺陷型病毒载体和病毒的感染性的方法
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
WO2020081490A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
|
|
JP7558575B2
(ja)
|
2018-10-22 |
2024-10-01 |
ユニバーシティ オブ ロチェスター |
レトロウイルスインテグラーゼ－Ｃａｓ９融合タンパク質を使用した指向性非相同ＤＮＡ挿入によるゲノム編集
|
|
EP3870600A1
(en)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
WO2020097269A1
(en)
|
2018-11-06 |
2020-05-14 |
Calidi Biotherapeutics, Inc. |
Enhanced systems for cell-mediated oncolytic viral therapy
|
|
AU2019381460A1
(en)
|
2018-11-16 |
2021-06-17 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting Utrophin gene
|
|
KR20210123289A
(ko)
|
2018-11-21 |
2021-10-13 |
인답타 세라뷰틱스 인코포레이티드 |
자연 살해 세포 서브세트의 증식을 위한 방법 및 관련 조성물 및 방법
|
|
KR20210135987A
(ko)
|
2018-11-30 |
2021-11-16 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd86 변이체 면역조절 단백질 및 그의 용도
|
|
BR112021009739A2
(pt)
*
|
2018-11-30 |
2021-10-19 |
Novartis Ag |
Vetores virais aav e usos dos mesmos
|
|
WO2020117898A1
(en)
|
2018-12-05 |
2020-06-11 |
Abeona Therapeutics Inc. |
Recombinant adeno-associated viral vector for gene delivery
|
|
US20220089670A1
(en)
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
DK3906066T5
(da)
|
2019-01-04 |
2024-08-05 |
Ultragenyx Pharmaceutical Inc |
Geneterapikonstruktioner til behandling af wilsons sygdom
|
|
CN113544267B
(zh)
|
2019-01-14 |
2025-04-18 |
罗切斯特大学 |
使用CRISPR-Cas进行靶向核RNA裂解和聚腺苷酸化
|
|
SG11202107645RA
(en)
|
2019-01-18 |
2021-08-30 |
Voyager Therapeutics Inc |
Methods and systems for producing aav particles
|
|
CN119390787A
(zh)
|
2019-01-31 |
2025-02-07 |
俄勒冈健康与科学大学 |
用于aav衣壳的使用转录依赖性定向进化的方法
|
|
BR112021015817A2
(pt)
|
2019-02-22 |
2021-10-13 |
The Trustees Of The University Of Pennsylvania |
Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn
|
|
BR112021016501A2
(pt)
|
2019-02-25 |
2021-10-26 |
Novartis Ag |
Composições e métodos para tratar distrofia cristalina de bietti
|
|
WO2020174369A2
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
SG11202108480UA
(en)
|
2019-02-26 |
2021-09-29 |
Univ Pennsylvania |
Compositions useful in treatment of krabbe disease
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
AU2020229875B2
(en)
|
2019-02-27 |
2025-01-16 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
AR118465A1
(es)
|
2019-03-21 |
2021-10-06 |
Stridebio Inc |
Vectores de virus adenoasociados recombinantes
|
|
WO2020193636A1
(en)
|
2019-03-25 |
2020-10-01 |
Genethon |
Production of large-sized quasidystrophins using overlapping aav vectors
|
|
EP3947700A4
(en)
|
2019-04-01 |
2023-01-04 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
KR20220004987A
(ko)
|
2019-04-03 |
2022-01-12 |
리젠엑스바이오 인크. |
눈 병리에 대한 유전자 요법
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
ES2965341T3
(es)
|
2019-04-11 |
2024-04-12 |
Regenxbio Inc |
Métodos de cromatografía de exclusión por tamaño para la caracterización de composiciones de virus adenoasociados recombinantes
|
|
TW202103718A
(zh)
|
2019-04-19 |
2021-02-01 |
美商銳進科斯生物股份有限公司 |
腺相關病毒載體調配物及方法
|
|
CA3137284A1
(en)
|
2019-04-24 |
2020-10-29 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
TW202106879A
(zh)
|
2019-04-29 |
2021-02-16 |
美商航海家醫療公司 |
於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
KR20220004680A
(ko)
*
|
2019-04-29 |
2022-01-11 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
신규 aav 캡시드 및 이를 포함하는 조성물
|
|
CA3135539A1
(en)
|
2019-05-03 |
2020-11-12 |
Juliette HORDEAUX |
Compositions useful in treatment of metachromatic leukodystrophy
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
AR118928A1
(es)
|
2019-05-14 |
2021-11-10 |
Biomarin Pharm Inc |
Métodos de redosificación de vectores de terapia génica
|
|
CA3135271A1
(en)
|
2019-05-28 |
2020-12-03 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting dmpk gene
|
|
SG11202113052YA
(en)
|
2019-05-30 |
2021-12-30 |
Solid Biosciences Inc |
Recombinant herpesvirales vector
|
|
EP3990030A1
(en)
|
2019-06-27 |
2022-05-04 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
BR112021026866A2
(pt)
|
2019-07-02 |
2022-03-03 |
M6P Therapeutics |
Composições de vetor e métodos de seu uso para o tratamento de distúrbios do armazenamento lisossômico
|
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
US20220282276A1
(en)
|
2019-07-11 |
2022-09-08 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated virus
|
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
WO2021016453A1
(en)
|
2019-07-23 |
2021-01-28 |
University Of Rochester |
Targeted rna cleavage with crispr-cas
|
|
EP4007814A1
(en)
|
2019-07-26 |
2022-06-08 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
|
EP4004214A1
(en)
|
2019-07-26 |
2022-06-01 |
RegenxBio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
PH12022550270A1
(en)
|
2019-08-16 |
2022-11-21 |
Modalis Therapeutics Corp |
Method for treating muscular dystrophy by targeting lama1 gene
|
|
WO2021034920A1
(en)
*
|
2019-08-20 |
2021-02-25 |
St. Jude Children's Research Hospital, Inc. |
SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
|
|
AU2020336314A1
(en)
|
2019-08-26 |
2022-04-07 |
Regenxbio Inc. |
Treatment of diabetic retinopathy with fully-human post-translationally modified anti-VEGF Fab
|
|
US20220307013A1
(en)
|
2019-08-30 |
2022-09-29 |
The Regents Of The University Of California |
Gene fragment overexpression screening methodologies, and uses thereof
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
KR20220079857A
(ko)
|
2019-09-13 |
2022-06-14 |
루트거스, 더 스테이트 유니버시티 오브 뉴 저지 |
Aav-상용성 라미닌-링커 중합 단백질
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
EP4031673A1
(en)
|
2019-09-19 |
2022-07-27 |
Genethon |
Gene therapy expression system alleviating cardiac toxicity of fkrp
|
|
EP4031562A4
(en)
|
2019-09-20 |
2023-11-01 |
University of Florida Research Foundation, Incorporated |
DETECTION OF ANTIBODIES AGAINST RAN PROTEINS FROM SERUM AND TISSUE LYSATES
|
|
US20220347298A1
(en)
|
2019-10-04 |
2022-11-03 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
AU2020362119A1
(en)
|
2019-10-07 |
2022-05-26 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
JP7640538B2
(ja)
|
2019-10-08 |
2025-03-05 |
トラスティーズ オブ ボストン カレッジ |
複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法
|
|
US20220362402A1
(en)
|
2019-10-08 |
2022-11-17 |
Exhaura, Ltd. |
Compositions and methods for ocular therapy
|
|
EP4045093A4
(en)
|
2019-10-14 |
2024-02-07 |
Duke University |
Compositions comprising novel prokaryotic sodium channels and associated methods
|
|
US11905523B2
(en)
|
2019-10-17 |
2024-02-20 |
Ginkgo Bioworks, Inc. |
Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
|
|
WO2021092298A1
(en)
*
|
2019-11-08 |
2021-05-14 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
EP4055030A4
(en)
*
|
2019-11-08 |
2024-05-22 |
President And Fellows Of Harvard College |
VIRAL CAPSID POLYPEPTIDES
|
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
BR112022009895A2
(pt)
*
|
2019-11-28 |
2022-08-09 |
Regenxbio Inc |
Construtos de terapia de gene de microdistrofina e usos dos mesmos
|
|
TW202134440A
(zh)
*
|
2019-12-04 |
2021-09-16 |
美商聖加莫治療股份有限公司 |
用於生產重組aav之新穎組合物及方法
|
|
WO2021116138A1
(en)
|
2019-12-09 |
2021-06-17 |
Ucl Business Ltd |
Gene therapy composition and treatment for myh7-linked cardiomyopathy
|
|
BR112022011332A2
(pt)
|
2019-12-10 |
2022-08-23 |
Takeda Pharmaceuticals Co |
Vetor de vírus adeno-associado recombinante, vírus adeno-associado recombinante, e, método para tratar um indivíduo com síndrome de hunter
|
|
BR112022013027A2
(pt)
|
2019-12-31 |
2022-09-06 |
Swanbio Therapeutics Ltd |
Construtos aav-abcd1 melhorados e uso para tratamento ou prevenção de adrenoleucodistrofia (ald) e/ou adrenomieloeuropatia (amn)
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
US20230059395A1
(en)
|
2020-01-22 |
2023-02-23 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
|
|
JP2023512043A
(ja)
|
2020-01-29 |
2023-03-23 |
レジェンクスバイオ インコーポレーテッド |
ムコ多糖症ｉｖａの治療
|
|
BR112022015183A2
(pt)
|
2020-01-29 |
2022-12-20 |
Regenxbio Inc |
Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
|
|
JP2023513487A
(ja)
|
2020-02-02 |
2023-03-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｇｍ１ガングリオシドーシスを治療するのに有用な組成物
|
|
EP4100424A2
(en)
|
2020-02-07 |
2022-12-14 |
University of Rochester |
Targeted translation of rna with crispr-cas13 to enhance protein synthesis
|
|
US20230073250A1
(en)
|
2020-02-07 |
2023-03-09 |
University Of Rochester |
Ribozyme-mediated RNA Assembly and Expression
|
|
BR112022015921A2
(pt)
|
2020-02-14 |
2022-10-04 |
Ultragenyx Pharmaceutical Inc |
Terapia gênica para tratar o transtorno de deficiência de cdkl5
|
|
US20230136699A1
(en)
|
2020-02-28 |
2023-05-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene therapy for maple syrup urine disease
|
|
AU2021230476A1
(en)
|
2020-03-02 |
2022-10-20 |
Tenaya Therapeutics, Inc. |
Gene vector control by cardiomyocyte-expressed microRNAs
|
|
US20230085724A1
(en)
|
2020-03-05 |
2023-03-23 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
|
EP4118098A4
(en)
|
2020-03-11 |
2024-06-12 |
The Trustees of The University of Pennsylvania |
METHOD AND COMPOSITION FOR GENE DELIVERY USING AN MANIPULATED VIRUS PARTICLE
|
|
WO2021188892A1
(en)
|
2020-03-19 |
2021-09-23 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
|
EP4126936A1
(en)
|
2020-03-27 |
2023-02-08 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
|
EP4127170A1
(en)
|
2020-03-27 |
2023-02-08 |
University of Rochester |
Crispr-cas13 crrna arrays
|
|
WO2021195519A1
(en)
|
2020-03-27 |
2021-09-30 |
University Of Rochester |
Targeted destruction of viral rna by crispr-cas13
|
|
US20230129893A1
(en)
|
2020-03-31 |
2023-04-27 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
US20230131352A1
(en)
|
2020-04-01 |
2023-04-27 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
JP2023520927A
(ja)
|
2020-04-10 |
2023-05-22 |
ソラ・バイオサイエンシズ・エルエルシー |
タンパク質凝集障害の処置のための組成物および方法
|
|
WO2021211753A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
US20230220014A1
(en)
*
|
2020-04-20 |
2023-07-13 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
AU2021258194A1
(en)
|
2020-04-22 |
2022-11-24 |
Indapta Therapeutics, Inc. |
Natural killer (NK) cell compositions and methods for generating same
|
|
WO2021222168A2
(en)
|
2020-04-28 |
2021-11-04 |
Sola Biosciences Llc |
Compositions and methods for the treatment of tdp-43 proteinopathies
|
|
MX2022013963A
(es)
*
|
2020-05-05 |
2023-02-22 |
Univ Duke |
Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.
|
|
CN115803064A
(zh)
|
2020-05-12 |
2023-03-14 |
宾夕法尼亚州大学信托人 |
用于drg特异性降低转基因表达的组合物
|
|
MX2022014245A
(es)
|
2020-05-12 |
2023-02-22 |
Univ Pennsylvania |
Composiciones utiles en el tratamiento de la enfermedad de krabbe.
|
|
CN116801911A
(zh)
|
2020-05-13 |
2023-09-22 |
阿库斯股份有限公司 |
用于治疗slc26a4相关听力损失的组合物和方法
|
|
WO2021231538A2
(en)
|
2020-05-13 |
2021-11-18 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
MX2022014256A
(es)
|
2020-05-13 |
2023-01-11 |
Voyager Therapeutics Inc |
Redirección del tropismo de las cápsides de aav.
|
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
US20230234997A1
(en)
|
2020-06-05 |
2023-07-27 |
Sola Biosciences Llc |
Compositions and Methods for the Treatment of Synucleinopathies
|
|
AU2021292200A1
(en)
|
2020-06-17 |
2023-02-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of gene therapy patients
|
|
JP2023530171A
(ja)
|
2020-06-19 |
2023-07-13 |
ジェネトン |
筋肉内及び心臓内でのｓｇｃｇの適切な発現を可能にする遺伝子療法発現系
|
|
CN116209768A
(zh)
*
|
2020-07-03 |
2023-06-02 |
吉尼松公司 |
用于通过高变区交换工程化新杂合aav衣壳的方法
|
|
IL299638A
(en)
*
|
2020-07-07 |
2023-03-01 |
Univ Texas |
Adeno-linked virus vector for DWORF polypeptide
|
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
|
WO2022008711A1
(en)
|
2020-07-10 |
2022-01-13 |
Genethon |
A novel muscle-specific promoter
|
|
KR20230038503A
(ko)
|
2020-07-13 |
2023-03-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
샤르코-마리-투스 질환의 치료에 유용한 조성물
|
|
CA3185589A1
(en)
|
2020-07-15 |
2022-01-20 |
Douglas Matthew ANDERSON |
Targeted rna cleavage with dcasl3-rnase fusion proteins
|
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
MX2023000815A
(es)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composiciones y metodos para el tratamiento de trastornos neurologicos relacionados con la deficiencia de glucosilceramidasa beta.
|
|
CN116121274B
(zh)
*
|
2020-07-29 |
2024-11-19 |
北京三诺佳邑生物技术有限责任公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
IL300526A
(en)
|
2020-08-17 |
2023-04-01 |
Massachusetts Inst Technology |
Approaches to SHANK3 gene therapy
|
|
IL300728A
(en)
|
2020-08-19 |
2023-04-01 |
Sarepta Therapeutics Inc |
Adeno-associated virus vectors for the treatment of Rett syndrome
|
|
CA3190399A1
(en)
|
2020-08-24 |
2022-03-03 |
James M. Wilson |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
|
WO2022046988A1
(en)
|
2020-08-26 |
2022-03-03 |
The Trustees Of The University Of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
|
EP4209589A4
(en)
|
2020-09-04 |
2024-09-25 |
National University Corporation Kobe University |
Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna
|
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
WO2022060915A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
AU2021356667A1
(en)
|
2020-10-07 |
2023-06-08 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
JP2023544797A
(ja)
|
2020-10-07 |
2023-10-25 |
レジェンクスバイオ インコーポレーテッド |
脈絡膜上投与用の、高粘度製剤などの製剤
|
|
AU2021358964A1
(en)
|
2020-10-07 |
2023-05-25 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
WO2022076582A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Gene therapy for ocular manifestations of cln2 disease
|
|
MX2023004005A
(es)
|
2020-10-07 |
2023-06-06 |
Regenxbio Inc |
Formulaciones para administración supracoroidea tales como formulaciones de gel.
|
|
TW202229560A
(zh)
|
2020-10-09 |
2022-08-01 |
賓州大學委員會 |
治療法布瑞氏症之組成物及方法
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
US20230383313A1
(en)
|
2020-10-18 |
2023-11-30 |
The Trustees Of The University Of Pennsylvania |
Improved adeno-associated virus (aav) vector and uses therefor
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
KR20230093437A
(ko)
|
2020-10-28 |
2023-06-27 |
리젠엑스바이오 인크. |
안구 적응증을 위한 벡터화된 항-TNF-α 항체
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
TW202233844A
(zh)
*
|
2020-10-29 |
2022-09-01 |
賓州大學委員會 |
Aav衣殼及含有其之組成物
|
|
WO2022094295A1
(en)
|
2020-10-29 |
2022-05-05 |
Regenxbio Inc. |
Vectorized tnf-alpha antagonists for ocular indications
|
|
AU2021372262B9
(en)
|
2020-11-02 |
2025-05-15 |
Biomarin Pharmaceutical Inc. |
Process for enriching adeno-associated virus
|
|
JP2023548816A
(ja)
|
2020-11-03 |
2023-11-21 |
ファイザー・インク |
陰イオン交換クロマトグラフィーによるａａｖベクターの精製方法
|
|
CA3197936A1
(en)
|
2020-12-01 |
2022-06-09 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
|
EP4255500A1
(en)
|
2020-12-01 |
2023-10-11 |
The Trustees of The University of Pennsylvania |
Compositions and uses thereof for treatment of angelman syndrome
|
|
JP2023551903A
(ja)
|
2020-12-01 |
2023-12-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組織特異的標的化モチーフを有する新規組成物及びそれを含有する組成物
|
|
WO2022130172A1
(en)
|
2020-12-15 |
2022-06-23 |
Pfizer Inc. |
Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
|
|
MX2023007315A
(es)
|
2020-12-16 |
2023-08-22 |
Regenxbio Inc |
Método para producir una partícula de virus adenoasociado recombinante.
|
|
AU2021404944A1
(en)
|
2020-12-23 |
2023-07-06 |
Pfizer Inc. |
Methods for purification of aav vectors by affinity chromatography
|
|
CN117157108A
(zh)
|
2020-12-29 |
2023-12-01 |
阿库斯股份有限公司 |
用于治疗clrn1相关听力损失和/或视力损失的组合物和方法
|
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
|
TW202241479A
(zh)
|
2020-12-30 |
2022-11-01 |
美商安迅生物製藥公司 |
遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法
|
|
CN116981697A
(zh)
|
2021-01-14 |
2023-10-31 |
森迪生物科学公司 |
可分泌有效载荷调节
|
|
WO2022159662A1
(en)
|
2021-01-21 |
2022-07-28 |
Regenxbio Inc. |
Improved production of recombinant polypeptides and viruses
|
|
US20240108760A1
(en)
*
|
2021-01-25 |
2024-04-04 |
Trames Bio, Inc. |
Adeno-associated virus capsids and engineered ligand-gated ion channels for treating focal epilepsy and neuropathic pain
|
|
EP4284335A1
(en)
|
2021-02-01 |
2023-12-06 |
RegenxBio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
US11926842B2
(en)
*
|
2021-02-02 |
2024-03-12 |
University Of Massachusetts |
Use of inverted terminal repeats (ITRS) from adeno-associated virus serotypes 8 and RH.39 in gene therapy vectors
|
|
AU2022218196A1
(en)
|
2021-02-05 |
2023-08-10 |
Maze Therapeutics, Inc. |
Vectors comprising stuffer polynucleotide sequences
|
|
US20240115734A1
(en)
*
|
2021-02-09 |
2024-04-11 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
KR20230145386A
(ko)
|
2021-02-10 |
2023-10-17 |
리젠엑스바이오 인크. |
재조합 인간 이두로네이트-2-설파타아제(ids)를 사용한 점액다당류증 ii의 치료
|
|
IL305440A
(en)
|
2021-02-26 |
2023-10-01 |
Takeda Pharmaceuticals Co |
Preparation and methods for treating Fabry disease
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141377A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240191213A1
(en)
|
2021-03-19 |
2024-06-13 |
Adrenas Therapeutics, Inc. |
Gene therapies for 21-hydroxylase deficiency
|
|
US20240307553A1
(en)
|
2021-04-01 |
2024-09-19 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
WO2022216749A1
(en)
|
2021-04-05 |
2022-10-13 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
|
KR20230170022A
(ko)
|
2021-04-12 |
2023-12-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
척수 및 연수 근위축증(sbma) 치료에 유용한 조성물
|
|
MX2023012513A
(es)
|
2021-04-23 |
2023-12-15 |
Univ Pennsylvania |
Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen.
|
|
JP2024515715A
(ja)
|
2021-04-23 |
2024-04-10 |
ユニバーシティ オブ ロチェスター |
レトロウイルスインテグラーゼ－Ｃａｓ融合タンパク質を使用した指向性非相同ＤＮＡ挿入によるゲノム編集及び治療の方法
|
|
JP2024515902A
(ja)
|
2021-04-26 |
2024-04-10 |
アレクシオン ファーマ インターナショナル オペレーションズ リミテッド |
組織向性が改善されたアデノ随伴ウイルスベクターカプシド
|
|
WO2022232141A1
(en)
|
2021-04-26 |
2022-11-03 |
Regenxbio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
|
WO2022235614A2
(en)
|
2021-05-04 |
2022-11-10 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
|
US20240358857A1
(en)
|
2021-05-11 |
2024-10-31 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
EP4352079A4
(en)
*
|
2021-06-08 |
2025-05-07 |
NF2 Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING NEUROFIBROMATIC DISORDERS
|
|
AU2022291872A1
(en)
*
|
2021-06-18 |
2024-01-18 |
Dyno Therapeutics, Inc. |
Capsid variants and methods of using the same
|
|
CA3224755A1
(en)
|
2021-06-22 |
2022-12-29 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
|
US20240287493A1
(en)
*
|
2021-06-24 |
2024-08-29 |
University Of Utah Research Foundation |
Compositions and methods for treating pgm1 deficiency
|
|
KR20240051112A
(ko)
|
2021-07-01 |
2024-04-19 |
인답타 세라뷰틱스 인코포레이티드 |
조작된 자연 살해(nk) 세포 및 관련 방법
|
|
AU2022307365A1
(en)
*
|
2021-07-08 |
2024-02-01 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
|
US20240409955A1
(en)
|
2021-07-19 |
2024-12-12 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
|
US20240366788A1
(en)
*
|
2021-07-23 |
2024-11-07 |
Duke University |
Adeno-associated virus compositions and methods of use thereof
|
|
CA3227533A1
(en)
|
2021-07-30 |
2023-02-02 |
Toru Miyazaki |
Therapeutic agent for ischemic disease
|
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
IL310691A
(en)
|
2021-08-11 |
2024-04-01 |
Sana Biotechnology Inc |
Genetically modified primary cells for allogeneic cell therapy
|
|
JP2024534772A
(ja)
|
2021-08-11 |
2024-09-26 |
サナ バイオテクノロジー，インコーポレイテッド |
同種異系細胞療法用の遺伝子改変細胞
|
|
WO2023019227A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
EP4392570A4
(en)
*
|
2021-08-25 |
2025-07-16 |
Canbridge Pharmaceuticals Inc |
AAV PARTICLES COMPRISING A LIVER-TROPIC CAPSID PROTEIN AND AN ACID ALPHA-GLUCOSIDASE (GAA) AND THEIR USE FOR TREATING POMPE DISEASE
|
|
AU2022332298A1
(en)
*
|
2021-08-25 |
2024-03-14 |
Canbridge Pharmaceuticals, Inc. |
Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease
|
|
IL311096A
(en)
|
2021-08-31 |
2024-04-01 |
Scout Bio Inc |
Antigen binding molecules and their uses
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
KR20240067112A
(ko)
|
2021-09-30 |
2024-05-16 |
아카우오스, 인크. |
Kcnq4-연관 청력손실을 치료하기 위한 조성물 및 방법
|
|
TW202325845A
(zh)
|
2021-10-02 |
2023-07-01 |
賓州大學委員會 |
新穎aav衣殼及含其之組成物
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
US20230151372A1
(en)
*
|
2021-10-07 |
2023-05-18 |
Academia Sinica |
Composition and Method of Treatment for Heart Protection and Regeneration
|
|
US20250001006A1
(en)
|
2021-10-07 |
2025-01-02 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
IL311871A
(en)
|
2021-10-08 |
2024-06-01 |
Dyno Therapeutics Inc |
Capsid variants and methods of using them
|
|
US20250042958A1
(en)
|
2021-10-08 |
2025-02-06 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
|
JP2024537178A
(ja)
|
2021-10-08 |
2024-10-10 |
ソラ・バイオサイエンシズ・エルエルシー |
ｐ５３媒介性癌の処置のための組成物および方法
|
|
TW202333776A
(zh)
|
2021-10-12 |
2023-09-01 |
美商阿斯帕醫療公司 |
用於治療腦白質失養症的方法及組合物
|
|
CA3234811A1
(en)
|
2021-10-20 |
2023-04-27 |
Steven Goldman |
Rejuvenation treatment of age-related white matter loss
|
|
EP4423285A1
(en)
|
2021-10-28 |
2024-09-04 |
RegenxBio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
TW202334436A
(zh)
|
2021-11-02 |
2023-09-01 |
美商航海家醫療公司 |
Ａａｖ衣殼變異體及其用途
|
|
JP2024542015A
(ja)
|
2021-11-02 |
2024-11-13 |
ユニバーシティ オブ ロチェスター |
脳内でのｔｃｆ７ｌ２媒介性髄鞘再生
|
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
TW202334181A
(zh)
|
2021-11-17 |
2023-09-01 |
美商航海家醫療公司 |
Ａａｖ蛋白殼變異體及其用途
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
KR20240110849A
(ko)
|
2021-11-29 |
2024-07-16 |
상하이 레제네리드 테라피즈 컴퍼니 리미티드 |
Aadc/gdnf 폴리뉴클레오티드 및 이의 파킨슨병 치료에 있어서의 용도
|
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
WO2023114897A2
(en)
*
|
2021-12-15 |
2023-06-22 |
Homology Medicines, Inc. |
Methods and compositions for the production of adeno-associated virus
|
|
TW202340467A
(zh)
|
2022-01-10 |
2023-10-16 |
賓州大學委員會 |
有用於治療c9orf72介導之病症之組成物及方法
|
|
TW202338086A
(zh)
|
2022-01-10 |
2023-10-01 |
賓州大學委員會 |
有用於治療異染性白質失養症之組成物
|
|
US20250082777A1
(en)
|
2022-01-10 |
2025-03-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20250099620A1
(en)
|
2022-01-17 |
2025-03-27 |
Dinaqor Ag |
Gene therapy composition and treatment for dystrophin-related cardiomyopathy
|
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
|
IL314434A
(en)
|
2022-01-25 |
2024-09-01 |
Univ Pennsylvania |
AAV capsids for enhanced cardiac transduction and liver targeting neutralization
|
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
CN118679182A
(zh)
|
2022-02-02 |
2024-09-20 |
阿库斯股份有限公司 |
用于治疗前庭神经鞘瘤相关症状的抗vegf抗体构建体和相关方法
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
TW202346599A
(zh)
|
2022-02-08 |
2023-12-01 |
美商航海家醫療公司 |
Ａａｖ衣殼變異體及其用途
|
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
CA3244192A1
(en)
|
2022-02-21 |
2025-01-22 |
Shanghai Regenelead Therapies Co., Ltd |
VEGF-BINDING MOLECULE AND ITS PHARMACEUTICAL USE
|
|
EP4482970A1
(en)
|
2022-02-23 |
2025-01-01 |
Massachusetts Institute of Technology |
Methods for upregulating shank3 expression
|
|
US20250101382A1
(en)
|
2022-03-11 |
2025-03-27 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
US20250207126A1
(en)
|
2022-03-13 |
2025-06-26 |
Regenxbio Inc. |
Modified muscle-specific promoters
|
|
WO2023183623A1
(en)
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
|
WO2023196873A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
|
|
EP4504258A1
(en)
|
2022-04-06 |
2025-02-12 |
The Trustees of the University of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
|
JP2025512969A
(ja)
|
2022-04-06 |
2025-04-22 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｈｅｒ２陽性転移性乳がん及び他のがんを治療するための組成物及び方法
|
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
|
EP4508222A1
(en)
|
2022-04-11 |
2025-02-19 |
Centre National de la Recherche Scientifique |
Chemically-modified adeno-associated viruses
|
|
TW202404993A
(zh)
|
2022-04-11 |
2024-02-01 |
美商特納亞治療股份有限公司 |
具經工程化蛋白殼之腺相關病毒
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
US20250249127A1
(en)
|
2022-04-14 |
2025-08-07 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
|
US20250277004A1
(en)
|
2022-04-18 |
2025-09-04 |
Regenxbio Inc. |
Hybrid aav capsids
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
TW202417633A
(zh)
|
2022-05-03 |
2024-05-01 |
美商銳進科斯生物股份有限公司 |
用於眼適應症之載體化抗TNF-α抑制劑
|
|
EP4518972A2
(en)
|
2022-05-03 |
2025-03-12 |
RegenxBio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
CN118974284A
(zh)
|
2022-05-06 |
2024-11-15 |
诺华股份有限公司 |
新型重组aav vp2融合多肽
|
|
US20250295809A1
(en)
|
2022-05-13 |
2025-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
JP2025518052A
(ja)
*
|
2022-05-24 |
2025-06-12 |
ケイト セラピューティクス， インコーポレイテッド |
Ｘｌｍｔｍを処置するための組成物
|
|
AU2023279090A1
(en)
|
2022-06-02 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
IL317874A
(en)
|
2022-06-24 |
2025-02-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
|
|
EP4547690A1
(en)
|
2022-06-28 |
2025-05-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
|
KR20250060188A
(ko)
|
2022-06-30 |
2025-05-07 |
인답타 세라뷰틱스 인코포레이티드 |
조작된 자연 살해(nk) 세포 및 항체 요법의 조합 및 관련 방법
|
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
TW202435912A
(zh)
|
2022-08-03 |
2024-09-16 |
美商航海家醫療公司 |
用於穿過血腦屏障之組合物及方法
|
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
TW202413648A
(zh)
|
2022-08-25 |
2024-04-01 |
日商武田藥品工業股份有限公司 |
用於治療法布立氏病（ｆａｂｒｙ ｄｉｓｅａｓｅ）之組合物及方法
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2024064856A1
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of cardiomyopathy with aav gene therapy vectors
|
|
TW202421788A
(zh)
|
2022-09-22 |
2024-06-01 |
美商拜奧馬林製藥公司 |
用ａａｖ基因療法載體治療致心律不整性心肌病
|
|
EP4593955A1
(en)
|
2022-09-30 |
2025-08-06 |
RegenxBio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
|
WO2024077089A2
(en)
*
|
2022-10-04 |
2024-04-11 |
Siren Biotechnology, Inc. |
Modified cpg dinucleotides for recombinant viral vector production
|
|
JP2025534666A
(ja)
|
2022-10-11 |
2025-10-17 |
リジェネックスバイオ インコーポレイテッド |
操作された核酸調節エレメントならびにその使用方法
|
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
|
AU2023398931A1
(en)
|
2022-12-17 |
2025-07-10 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
|
IT202200026595A1
(it)
|
2022-12-22 |
2024-06-22 |
Fond Telethon Ets |
Nuovi inibitori di regolatori epigenetici
|
|
EP4646478A1
(en)
|
2023-01-06 |
2025-11-12 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
EP4649160A1
(en)
|
2023-01-12 |
2025-11-19 |
Nantes Université |
Chemically-modified adeno-associated virus
|
|
WO2024163747A2
(en)
|
2023-02-02 |
2024-08-08 |
University Of Rochester |
Competitive replacement of glial cells
|
|
WO2024163979A2
(en)
*
|
2023-02-02 |
2024-08-08 |
Codexis, Inc. |
Engineered aav polypeptides
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4665743A2
(en)
|
2023-02-17 |
2025-12-24 |
Biogen MA Inc. |
Rgd-containing peptides for delivering payloads
|
|
WO2024192281A2
(en)
|
2023-03-15 |
2024-09-19 |
Regenxbio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
CN120882872A
(zh)
|
2023-03-17 |
2025-10-31 |
罗切斯特大学 |
核酶介导的rna组装和表达
|
|
WO2024206226A1
(en)
*
|
2023-03-25 |
2024-10-03 |
Duke University |
Compositions comprising kidney-tropic aavs and methods of use thereof
|
|
WO2024211780A1
(en)
|
2023-04-07 |
2024-10-10 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024215653A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
WO2024220463A2
(en)
*
|
2023-04-17 |
2024-10-24 |
University Of Massachusetts |
Aav5 capsid with non-canonical amino acid incorporation and uses thereof
|
|
WO2024220389A2
(en)
*
|
2023-04-17 |
2024-10-24 |
University Of Massachusetts |
Aav2 variants and uses thereof
|
|
AU2024258816A1
(en)
|
2023-04-18 |
2025-10-23 |
Uniqure Biopharma B.V. |
Generation of adeno-associated virus capsid libraries for insect cells
|
|
AU2024258047A1
(en)
|
2023-04-18 |
2025-10-23 |
Uniqure Biopharma B.V. |
Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
|
|
WO2024226790A1
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
TW202449167A
(zh)
|
2023-04-26 |
2024-12-16 |
美商航海家醫療公司 |
用於治療肌肉萎縮性脊髓側索硬化症之組成物及方法
|
|
AU2024264889A1
(en)
|
2023-05-03 |
2025-11-13 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024229125A2
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to frataxin deficiency
|
|
AU2024266138A1
(en)
|
2023-05-03 |
2025-11-13 |
Manifold Biotechnologies, Inc. |
Methods and compositions for high-throughput protein delivery, screening, and detection
|
|
WO2024229389A1
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
CN121079310A
(zh)
|
2023-05-03 |
2025-12-05 |
沃雅戈治疗公司 |
用于治疗与cdkl5缺乏相关的病症的组合物及方法
|
|
AU2024266519A1
(en)
|
2023-05-03 |
2025-12-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
TW202444917A
(zh)
|
2023-05-04 |
2024-11-16 |
美商航海家醫療公司 |
Ａａｖ衣殼變異體及其用途
|
|
WO2024233422A1
(en)
|
2023-05-05 |
2024-11-14 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
|
WO2024233529A2
(en)
|
2023-05-07 |
2024-11-14 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024233999A2
(en)
|
2023-05-11 |
2024-11-14 |
University Hospitals Cleveland Medical Center |
Anxiolytic therapy
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2024238867A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2024241176A1
(en)
|
2023-05-24 |
2024-11-28 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of diseases with central nervous system disorders
|
|
WO2024258961A1
(en)
|
2023-06-12 |
2024-12-19 |
The Trustees Of The University Of Pennsylvania |
Aav gene therapy for mucopolysaccharidosis iiib
|
|
AR133098A1
(es)
|
2023-06-29 |
2025-08-27 |
Univ Pennsylvania |
Aav mutante con motivos dirigidos al sistema nervioso central y composiciones que lo contienen
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
WO2025017168A1
(en)
|
2023-07-19 |
2025-01-23 |
Genethon |
Novel optimized utrophin micro-genes
|
|
WO2025017169A1
(en)
|
2023-07-20 |
2025-01-23 |
Genethon |
Novel mididystrophins
|
|
WO2025035143A1
(en)
|
2023-08-10 |
2025-02-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of spinal muscular atrophy
|
|
WO2025042711A1
(en)
|
2023-08-18 |
2025-02-27 |
Eli Lilly And Company |
Engineered transferrin receptor binding peptides as well as methods of making and using the same
|
|
WO2025072604A1
(en)
|
2023-09-28 |
2025-04-03 |
University Of Rochester |
Rna-editing gene therapy approaches for treating myotonic dystrophy type 1 (dm1)
|
|
WO2025075963A1
(en)
|
2023-10-02 |
2025-04-10 |
Regenxbio Inc. |
Methods and formulations for treating mucopolysaccharidosis ii-associated hearing loss with recombinant human iduronate-2-sulfatase
|
|
WO2025080780A1
(en)
|
2023-10-10 |
2025-04-17 |
University Of Rochester |
Delivery and expression of prime editing crispr systems
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|
|
TW202535908A
(zh)
|
2023-11-02 |
2025-09-16 |
美商渤健麻塞諸塞州股份有限公司 |
中樞神經系統靶向之ａａｖ衣殼之重定向
|
|
WO2025102034A1
(en)
|
2023-11-10 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|
|
WO2025106374A1
(en)
|
2023-11-13 |
2025-05-22 |
Juno Therapeutics, Inc. |
Aav production method
|
|
WO2025106661A1
(en)
|
2023-11-14 |
2025-05-22 |
The Trustees Of The University Of Pennsylvania |
Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025122543A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
WO2025122536A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025122532A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
WO2025122548A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
WO2025137219A1
(en)
|
2023-12-21 |
2025-06-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025147436A1
(en)
|
2024-01-03 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025171001A1
(en)
|
2024-02-06 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for improved production of aav viral vectors
|
|
WO2025188625A1
(en)
|
2024-03-03 |
2025-09-12 |
Passage Bio, Inc. |
Recombinant adeno-associated virus for treatment of neurodegenerative disorders
|
|
US20250276095A1
(en)
|
2024-03-04 |
2025-09-04 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
|
|
WO2025207948A1
(en)
|
2024-03-27 |
2025-10-02 |
Biogen Ma Inc. |
Aav capsids for targeting human transferrin receptor
|
|
WO2025207932A1
(en)
|
2024-03-27 |
2025-10-02 |
Biogen Ma Inc. |
Aav capsids comprising anti-transferrin antibody domains
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
WO2025217230A1
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2025226841A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Gene therapy approach for treating disorders associated with tnnt2
|
|
WO2025226842A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Expression control by drg-expressed mirnas
|
|
WO2025235734A2
(en)
|
2024-05-09 |
2025-11-13 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
GB202407038D0
(en)
|
2024-05-17 |
2024-07-03 |
Axovia Therapeutics Ltd |
Novel Gene Therapy
|
|
WO2025242657A1
(en)
|
2024-05-21 |
2025-11-27 |
Shape Biopharmaceuticals Ag |
Lipopeptide building blocks and aggregates
|
|
WO2025250457A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Enhanced brain transduction by gene therapeutics
|
|
WO2026006341A1
(en)
|
2024-06-24 |
2026-01-02 |
Regenxbio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|